B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy

B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy

Rituximab exerts its clinical efficacy by its specific pattern of depletion of CD20 + B lymphocytes and it has been demonstrated that rituximab is an effective treatment for relapsing remitting multiple sclerosis. X-linked adrenoleukodystrophy (X-ALD), the most common monogenetic neuroinflammatory d...

Full description

Bibliographic Details
Main Authors: Hendrik Rosewich, Stefan Nessler, Wolfgang Brück, Jutta Gärtner
Format: Article
Language:English
Published: SAGE Publishing 2019-08-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756286419868133
id doaj-18e8827bd1504125bc38894d69abc5f3
record_format Article
spelling doaj-18e8827bd1504125bc38894d69abc5f32020-11-25T03:00:05ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642019-08-011210.1177/1756286419868133B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophyHendrik RosewichStefan NesslerWolfgang BrückJutta GärtnerRituximab exerts its clinical efficacy by its specific pattern of depletion of CD20 + B lymphocytes and it has been demonstrated that rituximab is an effective treatment for relapsing remitting multiple sclerosis. X-linked adrenoleukodystrophy (X-ALD), the most common monogenetic neuroinflammatory disorder, shares substantial overlap with multiple sclerosis in the neuropathological changes found in brain tissues in advanced stages of the disease. While there is no effective therapy for these patients, we hypothesized that rituximab might be effective in arresting the neuroinflammatory process. Our detailed clinical, imaging and immunological data revealed that rituximab is not effective in advanced stages of X-ALD and consequently should not be applied for compassionate use in these patients.https://doi.org/10.1177/1756286419868133
collection DOAJ
language English
format Article
sources DOAJ
author Hendrik Rosewich
Stefan Nessler
Wolfgang Brück
Jutta Gärtner
spellingShingle Hendrik Rosewich
Stefan Nessler
Wolfgang Brück
Jutta Gärtner
B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
Therapeutic Advances in Neurological Disorders
author_facet Hendrik Rosewich
Stefan Nessler
Wolfgang Brück
Jutta Gärtner
author_sort Hendrik Rosewich
title B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
title_short B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
title_full B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
title_fullStr B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
title_full_unstemmed B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy
title_sort b cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral x-linked adrenoleukodystrophy
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2864
publishDate 2019-08-01
description Rituximab exerts its clinical efficacy by its specific pattern of depletion of CD20 + B lymphocytes and it has been demonstrated that rituximab is an effective treatment for relapsing remitting multiple sclerosis. X-linked adrenoleukodystrophy (X-ALD), the most common monogenetic neuroinflammatory disorder, shares substantial overlap with multiple sclerosis in the neuropathological changes found in brain tissues in advanced stages of the disease. While there is no effective therapy for these patients, we hypothesized that rituximab might be effective in arresting the neuroinflammatory process. Our detailed clinical, imaging and immunological data revealed that rituximab is not effective in advanced stages of X-ALD and consequently should not be applied for compassionate use in these patients.
url https://doi.org/10.1177/1756286419868133
work_keys_str_mv AT hendrikrosewich bcelldepletioncanbeeffectiveinmultiplesclerosisbutfailedinapatientwithadvancedchildhoodcerebralxlinkedadrenoleukodystrophy
AT stefannessler bcelldepletioncanbeeffectiveinmultiplesclerosisbutfailedinapatientwithadvancedchildhoodcerebralxlinkedadrenoleukodystrophy
AT wolfgangbruck bcelldepletioncanbeeffectiveinmultiplesclerosisbutfailedinapatientwithadvancedchildhoodcerebralxlinkedadrenoleukodystrophy
AT juttagartner bcelldepletioncanbeeffectiveinmultiplesclerosisbutfailedinapatientwithadvancedchildhoodcerebralxlinkedadrenoleukodystrophy
_version_ 1724699505268359168

Similar Items